Is Miralax (Polyethylene Glycol) 17g/Dose packet a Keep Open Packet (KOP) or a Discard Open Packet (DOT)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 1, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Miralax (Polyethylene Glycol) 17g/Dose Packet: KOP or DOT?

Miralax (Polyethylene Glycol) 17g/Dose packets should be considered DOT (Discard Open Packet) based on FDA labeling and clinical guidelines. 1

Rationale for DOT Classification

FDA Labeling Requirements

  • The FDA label for Polyethylene Glycol specifically states that users should "ensure that the powder is fully dissolved before drinking" and "do not drink if there are any clumps" 1
  • The label further instructs to mix the powder in 4-8 ounces of beverage (cold, hot, or room temperature) and drink immediately after mixing 1
  • These requirements make it inappropriate for keeping open packets, as the medication must be fully dissolved and consumed promptly

Clinical Considerations

  • PEG 3350 (Miralax) is an osmotic laxative that works by attracting water into the colon to soften stool 2
  • The efficacy of the medication depends on proper dissolution and dosing (17g once daily) 3
  • Keeping open packets could lead to:
    • Inaccurate dosing if partial packets are used
    • Decreased efficacy due to moisture absorption from the environment
    • Potential contamination of the powder

Administration Guidelines

Proper Preparation

  • Each 17g packet should be completely dissolved in 4-8 ounces of liquid 1
  • The solution can be prepared with water, juice, coffee, or tea 2
  • The powder must be fully dissolved before consumption 1
  • Do not combine with starch-based thickeners used for difficult swallowing 1

Duration of Use

  • For general constipation, FDA labeling recommends not using for more than 7 days without consulting a doctor 1
  • For chronic idiopathic constipation, clinical guidelines indicate it can be used safely for up to 6 months 3, 2

Clinical Efficacy and Safety

  • PEG 3350 has demonstrated effectiveness for constipation with approximately 2.9 more complete spontaneous bowel movements per week compared to placebo 2
  • The medication is well-tolerated with minimal side effects including bloating, flatulence, and abdominal discomfort 2
  • Long-term studies have shown safety for up to 12 months of continuous use 4

Key Takeaway

Due to the requirement for complete dissolution before consumption, the need for precise dosing, and the potential for degradation or contamination if left open, Miralax 17g/Dose packets should be treated as DOT (Discard Open Packet) rather than KOP (Keep Open Packet).

References

Guideline

Constipation Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.